We present tetramer-associated T-cell receptor sequencing (TetTCR-Seq), a method to link T cell receptor (TCR) sequences to their cognate antigens in single cells at high throughput. Binding is determined using a library of DNA-barcoded antigen tetramers that is rapidly generated by in vitro transcription and translation. We applied TetTCR-Seq to identify patterns in TCR crossreactivity with cancer neo-antigens and to rapidly isolate neo-antigen-specific TCRs with no crossreactivity to the wild-type antigen.
The ability to link T cell antigens, peptides bound by the major histocompatibility complex (pMHC), to T cell receptor (TCR) sequences is essential for monitoring and treating immune-related diseases. Fluorescently labeled T cell antigen oligomers, such as pMHC tetramers, are widely used to identify antigen-binding T cells 1 . However, spectral overlap limits the number of pMHC tetramer species that can be studies in parallel and the extent of cross-reactivity that can be examined 1 . CyTOF with isotope-labeled pMHC tetramers can interrogate a larger number of antigen species simultaneously, but its destructive nature prevents the linkage of antigens bound to TCR sequences 1 .
DNA-barcoded pMHC dextramer technology has been used for the analysis of antigen-binding T cell frequencies to samples of more than 1,000 pMHCs for T cells sorted in bulk 2 . However, with bulk analysis, information on the binding of single or multiple peptides to individual T cells is lost. In addition, antigen-linked TCR sequences cannot be obtained, which is valuable for tracking antigen-binding T cell lineages in disease settings, TCR-based therapeutics development 3 , and for uncovering patterns in TCRantigen recognition 4 . Another limitation is the high-cost and long-duration associated with synthesizing peptides chemically 5 , which prevents the quick generation of a pMHC library that can be tailored to specific pathogens or neo-antigens in an individual.
To address these challenges, we developed TetTCR-Seq, for the high-throughput pairing of TCR sequences with potentially multiple pMHC species bound on single T cells. First, we constructed a large library of fluorescently labeled, DNA-barcoded (DNA-BC) pMHC tetramers in a rapid and inexpensive manner using in vitro transcription/translation (IVTT) ( Fig. 1a ). Next, tetramer-stained cells were singlecell sorted and the DNA-BC and TCRαβ genes were amplified by RT-PCR ( Fig. 1b) . A molecular identifier (MID) was included in the DNA-BC to provide absolute counting of the copy number for each species of tetramers bound to the cell. Finally, nucleotide-based cell barcodes were used to link multiple peptide specificities with their bound TCRαβ sequences ( Fig. 1b ). DNA-BC pMHC tetramers are compatible with isolation of rare antigen-binding precursor T cells 6 , making TetTCR-Seq a versatile platform to analyze both clonally expanded and precursor T cells.
As constructing large pMHC libraries via UV-mediated peptide exchange using traditionally synthesized peptide is costly with long turnaround times 5 , we use a set of peptide-encoding oligonucleotides that serve as both the DNA-BCs for identifying antigen specificities and as DNA templates for peptide generation via IVTT (Fig. 1a ). The IVTT step only adds a few hours once oligonucleotides are synthesized. This significantly reduces the cost (about 20-fold) and time (2-3 days instead of weeks) compared to synthesizing peptides chemically. pMHC tetramers generated by our IVTT method have similar performance as the synthetic-peptide counterparts ( Fig. 1c and Supplementary Fig. 1 and 2 ). DNA-BC conjugation did not interfere with staining and has comparable sensitivity to fluorescent readouts ( Supplementary Fig. 3 
and 4). Six main
TetTCR-Seq experiments were performed ( Supplementary Fig. 5 ). We first assessed the ability of TetTCR-Seq to accurately link TCRαβ sequences with pMHC binding from primary CD8 + T cells in human peripheral blood. In Experiment 1, we constructed a 96-peptide library consisting of well documented foreign and endogenous peptides bound to HLA-A2 ( Supplementary Table) and isolated dominant pathogen-specific T cells as well as rare precursor antigen-binding T cells from a healthy CMV sero-positive donor ( Fig. 1 , Supplementary Fig. 6, 7) . To test whether TetTCR-Seq can detect crossreactive peptides, we included a documented HCV wildtype (WT) peptide, HCV-KLV(WT) 7 , and 4 candidate altered peptide ligands (APL) with 1-2 amino acid (AA) substitutions ( Supplementary Table) .
An established HCV-KLV (WT) T cell clone 7 was spiked into the donor's sample to test its cross-reactive potential.
Bound peptides were classified by their MID counts using two criteria: an MID threshold derived from tetramer negative controls and a ratio of MID counts between the peptides above and below this threshold ( Fig. 1d and Supplementary Information). Using this classification scheme, we identified the HCV-KLV(WT) epitope from all spike-in cells sorted ( Fig. 1e , Supplementary Fig. 8a ). In addition, we discovered that all four APLs were also classified as binders. A separate experiment confirmed the binding of these APLs to the T cell clone (Fig. 1f ). These results show that TetTCR-Seq is able to resolve positively-bound peptides in primary T cells and identify up to five cross-reactive peptides per cell.
The majority of primary T cells were classified as binding one peptide ( Fig. 1g ). This result is expected because the probability of TCR cross-reactivity between similar peptides is higher than disparate ones 8, 9 . Among the peptides surveyed, we found a high degree of peptide diversity in the foreign-antigen-binding naïve T cells ( Fig. 1h ). This diversity reduced to two dominant peptides for CMV and influenza in the non-naïve repertoire 10 (Fig. 1h ). This is expected given the CMV sero-positive status and the high probability of influenza exposure or vaccination for this donor. The majority of cells within the endogenous-antigen-binding population bind MART1-A2L, which corroborates its high documented frequency 6, 10 (Fig. 1h ). Linked TCR and DNA-BC analysis revealed that TCRα V genes 12-2 and 12-1/12-2 dominate in MART1-A2L and YFV-LLW specific TCRs, respectively ( Fig. 1i) , which is consistent with other reports 11, 12 . TetTCR-Seq on a second CMV sero-positive donor (Experiment 2) verified the findings from Experiment 1 ( Supplementary Fig. 9 ). These results highlight the ability of TetTCR-Seq to accurately link pMHC binding with TCR sequences. Naïve T cells from healthy donors are a useful source of neo-antigen-binding TCRs 3 . However, most neo-antigens are 1 AA from the WT sequence, meaning that neo-antigen-binding TCRs can potentially cross-react with host cells to cause autoimmunity. Although clinical adverse effects caused by neo-antigen recognizing T cells cross-reacting with endogenous tissue have not been reported, possibly due to the lack of technology development, other forms of cross-reactivity have been reported to cause death in clinical trials 13 . We next applied TetATCR-Seq to study the extent of cancer antigen crossreactivity in healthy donor peripheral blood T cells and isolate neo-antigen (Neo)-specific TCRs with no cross-reactivity to wildtype counterpart antigen (WT). In Experiment 3, we surveyed 20 pairs of Neo-WT peptides that bind with high affinity to HLA-A2. pMHC tetramer-based selection of naïve T cells has an inherent risk of selecting T cells reactive to peptides that are not naturally processed. As such, peptides were also chosen based on previous evidence of tumor expression and T cell targeting 3, [14] [15] [16] ( Supplementary Table) . Neo and WT pMHC pools were labeled using two separate fluorophores, allowing sorting of three cell populations, Neo + WT -, Neo -WT + , and Neo + WT + ( Fig. 2a and Supplementary Fig. 10 ).
T cells with two detected peptide binders accounted for 84% of the Neo + WT + population, 98% of which belonged to a Neo-WT antigen-pair ( Supplementary Fig. 11 ). Cells in the Neo + WT + population bound 11 of the 20 Neo-WT antigen-pairs, indicating that Neo-WT cross-reactivity is wide-spread in the precursor T cell repertoire (Fig. 2b) . By analyzing the proportion of mono-and cross-reactive T cells from each Neo-WT pair, we observed that neo-antigens with mutations at fringe positions 3, 8, and 9 elicited significantly more cross-reactive T cells than the ones at center positions 4, 5, and 6 ( Fig. 2c ). This is consistent with observations made by others using alanine substitutions on peptides in a mouse model 17 .
TetTCR-Seq on a separate donor (Experiment 4) showed the same trend ( Supplementary Fig. 13 ), indicating that this property is conserved between donors for the peptides tested.
To test the feasibility of TetTCR-Seq to screen larger libraries, we assembled a 315 Neo-WT antigen-pair library and profiled T cell cross-reactivity in more than 1,000 Tetramer + CD8 + sorted single T cells from two donors (Experiment 5 and 6, Fig. 2d , and Supplementary Fig. 15,16 ). ELISA on all 315 pMHC species showed no difference in pMHC UV-exchange efficiency between detected and undetected peptides ( Supplementary Fig. 17 ). Similar to Experiment 3 and 4, neo-antigen mutations in the fringes have elevated percentages of cross-reactive T cells than mutations in the middle (Fig. 2e,f, Supplementary   Fig. 16j ). Using this larger dataset, we also found that neo-antigen mutations with high PAM1 values, a surrogate for chemical similarity related to evolutionary mutational probability 18 , have a significantly higher percentage of cross-reactive T cells than those with low PAM1 values (Fig. 2f, ) . Thus, in addition to mutation position, WT-binding T cells are more likely to recognize the neo-antigen if the mutated AA is chemically similar to the original. Additional, so far unaccounted variations still exist between peptides, highlighting the necessity for experimental screening against WT cross-reactivity when using neo-antigen based therapy in cancer.
We also assessed the utility of TetTCR-Seq to isolate neo-antigen-specific TCRs with no crossreactivity to WT. We generated primary cell lines, each derived from 5 sorted cells in the Neo + WT -, Neo -WT + , and Neo + WT + populations from Experiment 3 and 4. These cells lysed antigen-pulsed target cells in a manner that matched their gating scheme during sorting, independent of the choice of pMHC tetramer fluorophore (Fig. 2g ). Further TetTCR-Seq analysis of Neo + WTand Neo + WT + T cell lines showed unique TCRs in each cell line targeting a limited range of antigens ( Supplementary Fig. 19a and b) . Cytotoxicity test confirmed the cross-reactivity of Neo + WT + cell lines as identified by TetTCR-Seq ( Supplementary   Fig. 19c ). Lastly, the antigen-recognition of Jurkat76 cell lines transduced with TCRs identified from Experiment 3 and 4 matched their original specificities ( Fig. 2h, Supplementary Fig. 20 ). Together, our T cell line and TCR-transduced Jurkat experiments show that TetTCR-Seq is not only capable of identifying cross-reactive TCRs on a large scale but can also identify functionally reactive neo-antigen specific TCRs that are not cross-reactive to WT-peptide in a high-throughput manner, which could be valuable in TCR re-directed adoptive cell transfer therapy 3, 19 .
In conclusion, we show that TetTCR-Seq can accurately link TCR sequences with multiple antigenic pMHC binders in a high-throughput manner, which can be broadly applied to interrogate antigen-binding T cells in T cell populations, from infection to autoimmune disease and cancer immunotherapy, potentially even for individual patients. With methods emerging for predicting antigenic pMHCs for groups of TCR sequences 4 , TetTCR-Seq can not only facilitate development in this area but 6 also help to validate informatically predicted antigens. Lastly, TetTCR-Seq can be integrated with singlecell transcriptomics and proteomics to gain further insights into the connections between single T cell phenotype, and TCR sequence and pMHC-binding landscape 20 .
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